Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.
BPC-157 + TB-500 Protocol
Also known as: Healing Stack, Wolverine Stack
The BPC-157 + TB-500 combination is one of the most popular peptide stacks for injury recovery. The theory is that BPC-157's gut-healing and angiogenic properties complement TB-500's systemic tissue repair capabilities.
Risk Level
Medium RiskDifficulty
Intermediate| Class | Peptide |
| Category | Other Performance Compounds |
Mechanism of Action
BPC-157 promotes angiogenesis, modulates nitric oxide, and upregulates growth factor receptors. TB-500 promotes cell migration, blood vessel formation, and reduces inflammation through actin regulation. Together they theoretically address both local and systemic healing pathways, though no studies have examined the combination directly.
Dosing Research
Commonly referenced protocol: BPC-157 250-500 mcg + TB-500 2-2.5 mg, injected subcutaneously near injury site or systemically. Typically run 4-8 weeks. No clinical data on the combination exists.
Side Effects & Risks
Individual safety profiles of each compound apply. Theoretical concern about excessive angiogenesis. No data on drug interactions between the two. The combination is entirely based on user reports and theoretical synergy, not clinical evidence.
Research Studies
Related compounds
Semaglutide
PeptideSemaglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Clinical trials demonstrated average weight loss of 15-17% of body weight. It has become one of the most widely discussed medications in modern weight management.
Tirzepatide
PeptideTirzepatide is a dual GLP-1/GIP receptor agonist approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). It has demonstrated unprecedented weight loss efficacy in clinical trials, with participants losing up to 20-25% of body weight. It represents the cutting edge of pharmaceutical weight management.
Liraglutide
PeptideLiraglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Victoza, 1.8 mg) and obesity (Saxenda, 3.0 mg). It was the first GLP-1 agonist approved specifically for weight management. While effective, it has been largely superseded by semaglutide and tirzepatide in terms of weight loss efficacy.
PT-141
PeptidePT-141 (bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist that was FDA-approved in 2019 as Vyleesi for the treatment of hypoactive sexual desire disorder in premenopausal women. Unlike PDE5 inhibitors, it acts centrally through the melanocortin system to increase sexual desire rather than just facilitating erection mechanics. It is the only FDA-approved on-demand treatment targeting central sexual arousal pathways.
Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.